marketshareAI
Theme

RTW Biotech Opportunities Ltd

RTWFinancial Services
1.9700USD
-0.76%
Market Cap
643.65M
Volume
199.27k
15% of avg
P/E Ratio
NaN
EPS (TTM)
Beta
0.8
Day Range
1.9600p - 2.0000p
52 Week Range
1.0800p1.9700p2.0000p
1.9700p

Upcoming Events

December 31, 2025
FDA decision on MOLBREEVI approval
High Impact Event
Early Q1 2026
Potential U.S. launch of MOLBREEVI
High Impact Event
H1 2026
Topline data from the U.S. Phase 2 trial of CX11 expected
High Impact Event
H1 2026
Initial data for JADE-001 expected
High Impact Event
RTW
NEUTRAL

RTW Biotech Opportunities Ltd Included in FTSE 250 Index

The investment fund focused on the biopharmaceutical and medical technology sectors has been included in the FTSE 250 Index, reflecting positive momentum in the business.

RTW
NEUTRAL

RTW Biotech Opportunities Ltd Announces Retail Investor Webinar

The investment fund is hosting a webinar for retail investors to provide an update on the company.

RTW
NEUTRAL

RTW Biotech Opportunities Ltd Provides Monthly Valuation Update

The investment fund provides a monthly update on its net asset value and portfolio holdings.

RTW
VERY GOOD

Evommune Completes $150 Million IPO, Shares Surge on Debut

The biotechnology company has completed a $150 million IPO, representing a significant step-up in valuation from the fund's previous holding.

RTW
NEUTRAL

RTW Biotech Opportunities Ltd Announces Director Dealings

The asset management firm has announced changes to its major shareholders.

RTW
GOOD

RTW Biotech Opportunities Ltd Secures $75M Royalty Funding Agreement with Savara Inc.

The investment fund has secured a $75 million royalty funding agreement with a biopharmaceutical company, subject to regulatory approval of a rare disease treatment.

RTW
NEUTRAL

Novartis to Acquire Avidity Biosciences, a Key Holding of RTW Biotech Opportunities

The investment fund RTW Biotech Opportunities Ltd announces that its portfolio company Avidity Biosciences is being acquired by Novartis for $12 billion.

RTW
NEUTRAL

RTW Biotech Opportunities Announces Capital Allocation Plan After M&A Successes

The investment company announces a capital allocation plan to return additional funds to shareholders through share buybacks, following successful M&A transactions involving its portfolio companies.

RTW
VERY GOOD

Kailera Therapeutics secures $600 million Series B financing

The biopharmaceutical company has secured $600 million in Series B financing to advance its pipeline of obesity treatments, including its lead candidate KAI-9531 which is progressing to global Phase 3 trials.

RTW
NEUTRAL

RTW Biotech Opportunities Ltd Releases Monthly Valuation Update

The investment fund releases its monthly valuation update and factsheet, reporting on its portfolio holdings and performance.